관리-도구

편집 파일: 1649842269.M646547P28747.server.saraya-global.com,S=13656,W=13875:2,

Envelope-to: roya.rouzbehani@saraya.world
Delivery-date: Wed, 13 Apr 2022 17:31:09 +0800
Content-Type: text/html; charset=utf-8
From: Office WulfHoeflich <office.wulfhoeflich@thefuturebridge.com>
Subject: Unique Insights on Biopharma Business Trends & R&D Landscapes
Message-ID: <59639ed9-4204-72cc-5f84-79e986013140@thefuturebridge.com>
Content-Transfer-Encoding: quoted-printable
Date: Wed, 13 Apr 2022 09:30:23 +0000 (UTC)
MIME-Version: 1.0
Reply-To: office.wulfhoeflich@thefuturebridge.com
To: roya.rouzbehani@saraya.world

Dear roya,</=
span> My name is Wu=
lf H=C3=B6flich and I head the Business Development for FutureBridge - a Re=
search & Advisory firm providing techno-commercial insights and advisory on=
 the future of industries from a 1-to-25-year perspective. We support most =
Fortune 500 players like Roche, DSM, Reckitt Benckiser, STADA, Nest=
le, Clariant, 3M, BASF, etc. I am writing to you as we =
have a unique proposition for SARYRA on t=
he Future of Pharma/Biotech industry ecosystem and we beli=
eve that reaching out to you would be most advisable given the ambit and re=
sponsibility of your profile. Our insights and intelligence pro=
gram is being used by industry leaders to understand and act on key areas s=
uch as R&D Productivity, new opportunities in terms of<str=
ong> MoAs and targets, R&D and clinical t=
rials trends, evolving clinical trial strategies =
and set-ups such as virtual clinical trials and </=
strong>virtual R&D centers. Our discussion will also exhibit cases on <stro=
ng>patient centric clinical trials, clinical tria=
ls analytics and competitive intelligence, secondary use o=
f clinical data, incorporation of digital technolo=
gies, application of digital technologies, and revisiting processe=
s to make it future ready, new partnerships, new risk shar=
ing business models, and more. We are keen to s=
hare with you how Biopharma companies are evaluating potential business cas=
es in the fields of Gene therapy, personalized</st=
rong> medicine, targeted delivery and combination of drug =
and device. It will be inspiring to discuss how market players are evaluati=
ng business models and aligning their clinical trials strategy and revampin=
g their R&D programs, R&D facilities, etc. It may also be inter=
esting for you to see how your peers are orienting themselves to improve R&=
D productivity, reducing risk of failure, and selection of highly promising=
 assets backed by scientific proofs, and collaborating at each level of val=
ue chain to speed to market/clinic/patient. We would like to req=
uest forty five minutes of your time for a digital meeting (45 minutes only=
) in the coming week to introduce to you our <a href=3D"http://insidertrend=
s.futurebridge.com/r/da34d234d76f06eb7fdab4a8f?ct=3DYTo1OntzOjY6InNvdXJjZSI=
7YToyOntpOjA7czoxNDoiY2FtcGFpZ24uZXZlbnQiO2k6MTtpOjIzNDk2O31zOjU6ImVtYWlsIj=
tpOjIzNzc4O3M6NDoic3RhdCI7czoyMjoiNjI1Njk1ZWZiN2JkYzQzODkyNDU2OCI7czo0OiJsZ=
WFkIjtzOjg6IjExNTY0MDM2IjtzOjc6ImNoYW5uZWwiO2E6MTp7czo1OiJlbWFpbCI7aToyMzc3=
ODt9fQ%3D%3D&">unique hyper intelligence and insights program</a>. <br=
 />Would any of the following slots work for you? If yes, please write back=
 to me with your preference. If not, please suggest alternatives:</s=
pan> <table style=3D"font-family: Arial,Helvet=
ica,sans-serif; font-size: 14px; border-collapse: collapse;">
 <tbody>
 =20
 <tr>
 <td class=3D"fr-cell-fixed " style=3D"width: 3.=
3464%;"> Thursday</td>
 <td style=3D"width: 68.2977%;"> 21 April - 07.0=
0 to 07.45 CEST </td>
 </tr>=20
 <tr>
 <td class=3D"fr-cell-fixed " style=3D"width: 3.=
3464%;"> Friday</td>
 <td style=3D"width: 68.2977%;"> 22 April - 08.0=
0 to 08.45 CEST </td>
 </tr>=20
 <tr>
 <td class=3D"fr-cell-fixed " style=3D"width: 3.=
3464%;"> Monday</td>
 <td style=3D"width: 68.2977%;"> 25 April - 07.0=
0 to 07.45 CEST </td>
 </tr>=20
 <tr>
 <td class=3D"fr-cell-fixed " style=3D"width: 3.=
3464%;"> Tuesday</td>
 <td style=3D"width: 68.2977%;"> 26 April - 08.0=
0 to 08.45 CEST </td>
 </tr>=20
 <tr>
 <td class=3D"fr-cell-fixed " style=3D"width: 3.=
3464%;"> Wednesday</td>
 <td style=3D"width: 68.2977%;"> 27 April - 09.0=
0 to 09.45 CEST </td>
 </tr>
 </tbody>
 </table> Best Regards, Wulf H=C3=
=B6flich SVP =E2=80=93 Business Development - Dipl.-Ing. (Univ.) </sp=
an> FutureBridge</span=
> UK 5, Chanc=
ery Lane, London EC4A 1BL United Kingdom T :+44 2034 787 =
710 <a href=3D"http://insidertrends.futurebridge.com/r/99efad154b85fd28d0fc=
4460e?ct=3DYTo1OntzOjY6InNvdXJjZSI7YToyOntpOjA7czoxNDoiY2FtcGFpZ24uZXZlbnQi=
O2k6MTtpOjIzNDk2O31zOjU6ImVtYWlsIjtpOjIzNzc4O3M6NDoic3RhdCI7czoyMjoiNjI1Njk=
1ZWZiN2JkYzQzODkyNDU2OCI7czo0OiJsZWFkIjtzOjg6IjExNTY0MDM2IjtzOjc6ImNoYW5uZW=
wiO2E6MTp7czo1OiJlbWFpbCI7aToyMzc3ODt9fQ%3D%3D&"></a> <a href=3D"htt=
p://insidertrends.futurebridge.com/r/99efad154b85fd28d0fc4460e?ct=3DYTo1Ont=
zOjY6InNvdXJjZSI7YToyOntpOjA7czoxNDoiY2FtcGFpZ24uZXZlbnQiO2k6MTtpOjIzNDk2O3=
1zOjU6ImVtYWlsIjtpOjIzNzc4O3M6NDoic3RhdCI7czoyMjoiNjI1Njk1ZWZiN2JkYzQzODkyN=
DU2OCI7czo0OiJsZWFkIjtzOjg6IjExNTY0MDM2IjtzOjc6ImNoYW5uZWwiO2E6MTp7czo1OiJl=
bWFpbCI7aToyMzc3ODt9fQ%3D%3D&">www.futurebridge.com</a> 
<img src=3D"https://insidertrends.futurebridge.com/media/images/fb_logo.=
jpg" />
 
Please consider the environment before printing this email.</sp=
an> FutureBridge=C2=AE =
is a registered trademark of Cheers Interactive (India) Private Limited. <b=
r /> =E2=80=9CThis message is intended only for the person or en=
tity to which it is addressed and contains confidential, proprietary and/or=
 privileged information. If you have received this message in error, please=
 notify the sender immediately and delete this message from your system. Re=
asonable precautions have been taken to ensure that this message is virus-f=
ree. However, Cheers Interactive (India) Private Limited does not accept an=
y responsibility whatsoever for any loss or damage arising from the use of =
this message or any attachments herein=E2=80=9D. =

<div style=3D"text-align: center;">
 FutureBridge, Stadsplateau 7 ,Ultrecht, =
3521 AZ, Ultrecht, The Netherlands<a href=3D"http://insidertren=
ds.futurebridge.com/email/unsubscribe/625695efb7bdc438924568_____unsubscrib=
e_____Meeting%20Ask_____MtgAsk- Pharma - Early R&D - 79 - 220412 - MDB Reru=
n">Unsubscribe</a> <a href=3D"http://insidertrends.futurebridge.co=
m/email/unsubscribe/625695efb7bdc438924568_____preference_____Meeting%20Ask=
_____MtgAsk- Pharma - Early R&D - 79 - 220412 - MDB Rerun">Manage Preferen=
ces</a>
</div><img height=3D"1" width=3D"1" src=3D"http://insidertrends.futurebridg=
e.com/email/625695efb7bdc438924568.gif" alt=3D"" />